Jazz Moves to Snap Up Cannabinoid Company, Bolster Neurology Pipeline
Through the purchase, Jazz will add to its stable GW’s lead product, Epidiolex, a cannabinoid approved in the U.S. and Europe for seizures in rare diseases Lennox-Gastaut Syndrome and Dravet Syndrome, and in the U.S. only for seizures in Tuberous Sclerosis Complex.
Jazz has been actively developing its neurology pipeline over the past two years. In October 2020, the company purchased JZP-150, an FAAH inhibitor program developed by SpringWorks Therapeutics, for $35 million up front. Jazz now has the compound in Phase II testing for post-traumatic stress disorder.
The year before, the company acquired Cavion Inc. and its lead asset JZP-385, a T-type calcium channel moderator in Phase II for essential tremor. The company is planning a Phase IIb trial for the candidate early this year.
Ireland-based Jazz also announced positive top-line data in October 2020 from a Phase III trial in idiopathic hypersomnia for Xywav, part of its existing sleep disorder franchise. Xywav had previously nabbed U.S. Food and Drug Administration approval in July, for treating cataplexy and excessive daytime sleepiness in patients with narcolepsy. Jazz now has four marketed drugs in sleep disorders.
According to a statement, the addition of GW’s portfolio will contribute to double-digit revenue growth for Jazz. Epidiolex has reached $510 million in annual sales since its launch two years ago.
“We have a shared vision of developing and commercializing innovative medicines that address significant unmet needs in neuroscience and an approach of putting patients first,” said Justin Gover, CEO of GW Pharmaceuticals. “Together, we will have an opportunity to reach and impact more patients through a broader portfolio of neuroscience-focused therapies than ever before.”
In addition to Epidiolex, the first plant-derived cannabinoid approved by the FDA, Jazz will also acquire Sativex, an oral spray formulation of both delta-9-tetrahydracannibinol and cannabidiol approved in the EU for spasticity due to multiple sclerosis. FW also has nabiximols in Phase III testing in the U.S. for spasticity associated with multiple sclerosis and spinal cord injury. The company also has cannabidivarin, a non-psychoactive cannabis extract, in Phase II testing for epilepsy and autism spectrum disorder, as well as other candidates for schizophrenia and neonatal hypoxic-schemic encephalopathy.
Both companies’ boards of directors have approved the sale, though GW shareholders must still do the same. If approved, Jazz will pay $220.00 per American Depositary Share (ADS) for GW, which will include $200.00 in cash and $20.00 in Jazz ordinary shares, for a total of $7.2 billion ($6.7 billion net of GW cash). The sale must also get regulatory approval in the U.K.